SCHEMBL4265161

SCHEMBL4265161

CCN(C(=O)C=Cc1ccc(C(=O)Nc2ccccc2NC(=O)O)cc1)c1cccnc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 4/20 0.48
NPSR1 Q6W5P4 2/20 0.44
MAPK1 P28482 1/20 0.44
NAMPT P43490 2/20 0.44
HTT P42858 1/20 0.44
CYP2C19 P33261 1/20 0.42
GFER P55789 1/20 0.42
HPGD P15428 1/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
TP53 P04637 1/20 0.41
KMT2A Q03164 1/20 0.41
TRPV1 Q8NER1 1/20 0.41
TRPM8 Q7Z2W7 2/20 0.41
SNCA P37840 1/20 0.41
KDM4E B2RXH2 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4269534 0.90 HDAC1 (0.61) HDAC1NAMPT
SCHEMBL4265151 0.74 HDAC1 (0.66) HDAC1NAMPTSMN1; SMN2KMT2A
SCHEMBL4265144 0.74 HDAC1 (0.66) HDAC1NAMPTSMN1; SMN2KMT2A
SCHEMBL4259725 0.72 TRPM8 (0.53) HDAC1MAPK1NAMPTKMT2ATRPM8
SCHEMBL20250757 0.71 TRPM8 (0.68) HPGDALDH1A1KMT2ATRPM8
SCHEMBL13949683 0.71 HDAC1 (0.72) HDAC1NAMPTKMT2A
SCHEMBL4254167 0.71 HDAC1 (0.72) HDAC1NAMPTKMT2A
SCHEMBL2686342 0.68 KMT2A (0.54) HDAC1MAPK1CYP2C19HPGDALDH1A1
SCHEMBL3948489 0.68 HDAC1 (0.65) HDAC1NAMPT
SCHEMBL6671752 0.68 HTT (0.65) NPSR1MAPK1HTTCYP2C19GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE METHYLGENE INC. (CA) 2009-01-22 US disclosed
US-7282608-B2 Inhibitors of histone deacetylase METHYLGENE, INC. (CA) 2007-10-16 US disclosed
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents METHYLGENE, INC. (CA) 2006-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023734-A1 INHIBITORS OF HISTONE DEACETYLASE HDAC1, HDAC11, HDAC6 HDAC1 1/4885NPSR1 4616/4885MAPK1 1307/4885
US-20060020131-A1 Aryl amide, -sulfonamide, or -urea derivatives; antiproliferative, antitumor, anticarcinogenic, and/or antimetastasis agents HDAC1, AADAC, HDAC11 HDAC1 1/4885NPSR1 2647/4885MAPK1 1781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.